About UDP-N-acetylglucosamine transporter
UDP-N-acetylglucosamine transporter (SLC35A3) is a protein
from Homo sapiens identified by UniProt accession
Q9Y2D2, 325 residues long.
MolForge cross-references it against 0 known binders and
152 disease associations.
Target properties
| Protein name | UDP-N-acetylglucosamine transporter |
| UniProt accession | Q9Y2D2 |
| Gene | SLC35A3 |
| Organism | Homo sapiens |
| Length | 325 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (152)
Diseases linked to this target (Open Targets).
- autism spectrum disorder - epilepsy - arthrogryposis syndrome · score 0.66
- Autism spectrum disorder-epilepsy-arthrogryposis syndrome · score 0.46
- epilepsy syndrome · score 0.37
- distal arthrogryposis · score 0.37
- developmental disorder of mental health · score 0.37
- genetic disorder · score 0.33
- neurodegenerative disease · score 0.28
- gut microbiome measurement · score 0.23
- arthrogryposis multiplex congenita · score 0.17
- autosomal recessive spondylocostal dysostosis · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y2D2-F1 | alphafold | PREDICTED | 89.32 | — |
Amino-acid sequence (325 residues)
MFANLKYVSL GILVFQTTSL VLTMRYSRTL KEEGPRYLSS TAVVVAELLK IMACILLVYK DSKCSLRALN RVLHDEILNK PMETLKLAIP SGIYTLQNNL LYVALSNLDA ATYQVTYQLK ILTTALFSVS MLSKKLGVYQ WLSLVILMTG VAFVQWPSDS QLDSKELSAG SQFVGLMAVL TACFSSGFAG VYFEKILKET KQSVWIRNIQ LGFFGSIFGL MGVYIYDGEL VSKNGFFQGY NRLTWIVVVL QALGGLVIAA VIKYADNILK GFATSLSIIL STLISYFWLQ DFVPTSVFFL GAILVITATF LYGYDPKPAG NPTKA
Explore UDP-N-acetylglucosamine transporter with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets